15 Mar 2021 – Destiny Pharma Announces Agreement with NIAID
Monday March 15, 2021
Monday March 15, 2021
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection
Brighton, United Kingdom, 15 March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it has entered into a Non-Clinical Evaluation Agreement (NCEA) with the US government’s National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, to evaluate the preclinical safety of a dermal formulation of XF-73. Under NIAID’s suite of preclinical services, NIAID-funded contractors will conduct these clinically enabling safety studies.
Destiny Pharma is developing a novel formulation of XF-73 for the prevention of infection associated with open wounds and broken skin. This programme has previously demonstrated positive results across a range of preclinical efficacy studies and two Phase 1 dermal irritancy trials.
Destiny Pharma will utilize NIAID’s preclinical services programme to complete the preclinical safety studies that will support the planned clinical development in serious wound infections. Destiny Pharma will provide the XF-73 formulation to be tested in these preclinical studies and the project is planned to complete in 2022.
Neil Clark, CEO of Destiny Pharma, said: “We are very pleased to be working with NIAID again on another XF-73 project to build on the existing data that supports its potential as a novel product to prevent and/or treat serious dermal infections, including those associated with diabetic foot ulcers (DFUs) and burn wounds. This study will enable us to finalise the selection of our dermal indication. XF-73 is also in clinical development as a nasal gel formulation for the prevention of post-surgical infections and is on plan to report results from a Phase 2b study at the end of this month.”
XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of postsurgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. The Company is expecting to announce
data from its recently completed Phase 2b clinical study testing the XF-73 nasal gel as a novel product for the prevention of post-surgical infections by the end of March 2021. It has been awarded both qualifying infectious disease product (QIDP) and Fast Track status by the US FDA. XF-73 also has potential as a treatment in a range of dermal indications and is being examined in established research collaborations and in this new agreement with NIAID. Destiny Pharma has also invested in a programme of work to identify formulations tailored to the dermal infection market.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a
Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com